Cell and Gene Therapy Supply Chain/Logistics Market Report 2025

The cell and gene therapy supply chain/logistics market size has grown rapidly in recent years. It will grow from $1.41 billion in 2024 to $1.58 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to growth in prevalence of chronic diseases, efficient use of supply chain requirements, rise in maintenance the drug integrity, evolved regulatory frameworks, increased emphasis on risk mitigation and compliance.

The cell and gene therapy supply chain/logistics market size is expected to see rapid growth in the next few years. It will grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to expansion of personalized medicine, development of cell-free therapies, growing prevalence of chronic diseases, growing global cell therapy manufacturing market, efficient use of supply chain requirements. Major trends in the forecast period include increased research and development expenditure, adoption of advanced technologies, favorable initiatives and programs for easier access, partnerships and collaborations between cell and gene therapy companies, supply chain providers, and logistics companies, providing of customizable services to support any point of patient identification.

The growing demand for cell and gene therapies is propelling the cell and gene therapy supply chain and logistics market. These advanced medical treatments modify cells or genes to address diseases, offering potential breakthroughs for previously untreatable conditions. Proper temperature and storage conditions are crucial for these therapies, which supply chain and logistics services can provide through sourcing, distribution, and storage solutions. For example, the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported a 10% increase in the number of gene therapies in Phase III clinical trials in Q3 2023, marking the first quarterly rise since Q3 2022. As a result, the increasing demand for cell and gene therapies is driving the growth of the cell and gene therapy supply chain and logistics market.

The anticipated growth of the cell and gene therapy supply chain/logistics market is further supported by the increasing demand for personalized medicine. Personalized medicine involves tailoring medical decisions, interventions, and drug therapies to individual patients, and the supply chain/logistics services for cell and gene therapies play a critical role in delivering these precision medicines safely and effectively. Temperature monitoring is incorporated to maintain integrity throughout the supply chain. As of October 2022, there were over 75,000 genetic testing products and 300 personalized medicines, highlighting the growing demand for personalized medical solutions, according to reports published by STAT, a US-based health-oriented news company. Therefore, the rising demand for personalized medicine is a key driver of the growth in the cell and gene therapy supply chain/logistics market.

The adoption of modern technology platforms stands out as a key trend in the cell and gene therapy supply chain/logistics markets. Major companies within this sector are actively developing advanced technology platforms to enhance their position in the market. For instance, in April 2023, AmerisourceBergen Corporation, a US-based healthcare company specializing in cell and gene therapy supply chain logistics, introduced the Cell and Gene Therapy (CGT) Integration Hub. This innovative hub, powered by AmerisourceBergen’s customer relationship management (CRM) system, can seamlessly integrate into the biopharma platform, enabling improved monitoring of the development and delivery processes for cell and gene therapies.

Leading companies in the cell and gene therapy supply chain/logistics sector are concentrating on introducing next-generation solutions, including off-the-shelf cell orchestration platforms. These platforms offer streamlined supply chain management, pre-designed modules, industry-proven processes, rapid deployment, and integration capabilities. For example, in January 2022, TrakCel Limited, a UK-based software company, launched OCELLOS Lite, a pre-designed, modular, and validated solution for managing the supply chain and logistics of cell and gene therapies. OCELLOS Lite facilitates supply chain process management from clinical development phases to commercialization and boasts quick deployment, making it one of the most straightforward and rapid solutions.

In April 2022, Cryoport Systems LLC, a US-based provider of temperature-controlled logistics services, acquired Cell&Co BioServices for $6.2 million. This strategic acquisition enabled Cryoport to expand its global supply chain network and better cater to the needs of the regenerative medicine industry. Cell&Co BioServices, based in France, is a supply chain management services provider for biological, pharmaceutical, and clinical samples throughout their life cycle.

Major companies operating in the cell and gene therapy supply chain/logistics market include AmerisourceBergen Corporation, United Parcel Service, Thermo Fisher Scientific Inc., Avantor Sciences, Lonza Group AG, Arvato Group, Catalent Inc., Charles River Laboratories International, Parexel International Corporation, Cytiva, Almac Group, World Courier, Sharp Packaging Services, PCI Pharma Services, Cryoport Inc., Brooks Life Sciences, BioLife Solutions Inc., Biocair Inc., QuickSTAT, Clarkston Consulting Inc., Central Pharma, TrakCel limited, MAK-SYSTEM International Group, Hypertrust Patient Data Care GmbH, Atelerix Ltd., Polar Express Transportation, Be The Match BioTherapies Inc., Yourway Biopharma Services Company, Azenta Life Sciences Inc., Biostor Ltd.

North America was the largest region in the cell and gene therapy supply chain/logistics market in 2024. The regions covered in the cell and gene therapy supply chain/logistics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy supply chain/logistics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Cell and gene therapy supply chain and logistics encompass the systematic coordination and management of materials, information, and resources essential for the development, production, and distribution of cell and gene therapies, ensuring their safe and effective administration to patients. These services deliver advanced treatments to patients, upholding the highest standards of safety and efficacy throughout the entire supply chain.

Various software solutions play crucial roles in these processes, including cell orchestration platforms, enterprise manufacturing systems, inventory management systems, laboratory information management systems, logistics management systems, patient management systems, quality management systems, and tracking and tracing systems. A cell orchestration platform is a software or technological platform facilitating the coordination, management, and integration of diverse processes related to cell therapy development, manufacturing, and delivery. It streamlines and automates tasks associated with cell sourcing, manufacturing, quality control, logistics, patient tracking, and data management. These platforms are deployed as cloud-based or on-premises solutions and are utilized in cryogenic shippers, cryogenic storage freezers, ultra-low freezers, cold chain management systems, shipment, storage medium, cryogenic packout kits, and other components. Applications include donor eligibility assessment, sample collection, manufacturing, logistics, patient verification, and treatment follow-up. End-users encompass biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations.

The cell and gene therapy supply chain/logistics research report is one of a series of new reports that provides cell and gene therapy supply chain/logistics market statistics, including the cell and gene therapy supply chain/logistics industry's global market size, regional shares, competitors with a cell and gene therapy supply chain/logistics market share, detailed cell and gene therapy supply chain/logistics market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy supply chain/logistics industry. This cell and gene therapy supply chain/logistics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell and gene therapy supply chain and logistics market includes revenues earned by entities by providing sourcing and collection, quality testing, distribution, and transportation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.